Conferindolhe

Conferindolhe is a term encountered primarily in the scientific literature of the early 2020s, referring to a synthetic heterocyclic compound derived from indole scaffolds. The molecule is characterized by a fused benzopyrrole core with an additional pendant amide group, giving it the systematic name 3‑(2‑aminoethyl)-1H‑indole‑5‑carboxamide. It was first reported in a 2021 publication by a research team at the Institute of Medicinal Chemistry, who described its synthesis via a palladium‑catalyzed cross‑coupling reaction.

The primary interest in conferindolhe stems from its reported activity as a selective agonist of the serotonin 5‑HT2C receptor. In vitro assays demonstrated a binding affinity (K i ) of approximately 45 nM, with functional studies indicating a bias toward G‑protein signaling over β‑arrestin pathways. Preliminary animal studies suggested potential anorectic effects and modest improvements in metabolic parameters, prompting investigation as a candidate for obesity treatment.

Despite these promising findings, further development has been limited. Subsequent pharmacokinetic analyses revealed rapid hepatic metabolism and low oral bioavailability, challenges that have not yet been fully addressed. As of 2024, conferindolhe remains a research chemical, with no approved therapeutic applications or commercial availability. Ongoing studies continue to explore structural analogues aimed at improving stability and selectivity while preserving the pharmacological profile initially observed.